Aktienanalyse zu Corbus Pharmaceuticals Holdings Inc (CRBP)CRBPCorbus Pharmaceuticals Holdings Inc

Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company. The Company has a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The Company’s oncology pipeline comprises two experimental drugs targeting solid tumors: CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFB expressed on cancer cells. CRB-701 is a monoclonal antibody attached to a monomethyl auristatin E (MMAE) cytotoxic payload using a proprietary linker technology. The pipeline also includes CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. CB1 inverse agonism is a clinically validated mechanism to induce weight loss. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Corbus Pharmaceuticals (CRBP) is a good buy right now due to its current price of $10.91, which is significantly lower than the analyst price targets of $33 and $48. The stock has shown strong momentum with a 20-day change of +21.63% and an RSI of 61.042, indicating bullish sentiment. However, the main risk is the negative earnings trend, with a reported EPS of -1.81 and a forward P/E of 0, reflecting ongoing losses that could impact future performance.

3 analysts cover CRBP: 3 rate it Buy, 0 Hold and 0 Sell. The average price target is 46.71.